FAK与PYK2协同调控IFN-γ信号重塑黑色素瘤免疫检查点阻断耐药
本研究在黑色素瘤中界定FAK(主支架)与PYK2(辅助)在IFN-γ介导的免疫检查点阻断耐药中的不同作用。无标记磷酸化蛋白质组学显示IFN-γ刺激驱动细胞骨架重塑、转录调控、mRNA剪接和核糖体RNA生物合成通路的广泛磷酸化。选择性FAK抑制显著抑制IFN-γ诱导的STAT1和PD-L1上调,加用PYK2阻断达最大抑制并增强CD8+ T细胞介导的肿瘤细胞毒性。抗PD-1耐药小鼠模型中高肿瘤FAK表达与治疗失败相关。
要点
- FAK是IFN-γ依赖的免疫检查点阻断耐药的主要驱动因子,PYK2起辅助作用。
- 选择性FAK抑制联合有限PYK2阻断可最大程度抑制STAT1/PD-L1上调并增强CD8+ T细胞毒性。
- 肿瘤FAK高表达与抗PD-1治疗失败相关,治疗后FAK下调者预后改善。
核心结论
- FAK是IFN-γ依赖性免疫检查点阻断耐药的主导驱动因子,PYK2发挥辅助作用。
- 选择性靶向FAK可能联合有限PYK2抑制克服黑色素瘤免疫检查点阻断耐药。
研究设计与样本
- 基础与转化研究:采用无标记磷酸化蛋白质组学、选择性FAK抑制与PYK2阻断、抗PD-1耐药小鼠黑色素瘤模型、TCGA-SKCM队列及GSE91061临床数据集、单细胞RNA测序。
主要发现
- IFN-γ刺激驱动细胞骨架重塑、转录调控、mRNA剪接和核糖体RNA生物合成通路的广泛磷酸化。
- 选择性FAK抑制显著抑制IFN-γ诱导的STAT1和PD-L1上调,加用PYK2阻断达最大抑制并增强CD8+ T细胞介导的肿瘤细胞毒性。
- 抗PD-1耐药小鼠模型中高肿瘤FAK表达与治疗失败相关。
- TCGA-SKCM队列显示FAK水平与免疫抑制基因特征相关;GSE91061数据集中治疗后FAK下调患者结局改善。
- 单细胞RNA测序区分肿瘤细胞内在FAK表达与免疫亚群中PYK2富集。
临床怎么用
- 对免疫检查点阻断耐药的黑色素瘤患者,可考虑评估肿瘤FAK表达作为耐药标志。
- 选择性FAK抑制联合有限PYK2阻断可能作为克服免疫检查点阻断耐药的策略。
局限性
- 证据主要来自临床前模型和回顾性队列分析,尚需前瞻性临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade has transformed melanoma therapy but is frequently limited by acquired resistance. Focal adhesion kinase (FAK) and its homolog PYK2 are nonreceptor tyrosine kinases that coordinate cell-matrix adhesion and cytoskeletal signaling. In this study, we define the distinct roles of FAK (as the principal scaffold) and PYK2 (in a supportive capacity) in IFN-γ-mediated immune checkpoint blockade resistance. Label-free phosphoproteomic profiling revealed that IFN-γ stimulation drives extensive phosphorylation across pathways governing cytoskeletal remodeling, transcriptional regulation, mRNA splicing, and ribosomal RNA biogenesis. Selective FAK inhibition markedly suppressed IFN-γ-induced signal transducer and activator of transcription 1 and PD-L1 upregulation, and the addition of PYK2 blockade achieved maximal suppression, culminating in enhanced CD8+ T-cell-mediated tumor cytotoxicity. In an anti-PD-1-resistant murine melanoma model, high tumoral FAK expression correlated with treatment failure. Analysis of The Cancer Genome Atlas-Skin Cutaneous Melanoma cohort showed that FAK levels associate with immunosuppressive gene signatures, whereas in an independent clinical dataset (GSE91061), patients exhibiting post-treatment downregulation of FAK experienced improved outcomes. Single-cell RNA sequencing distinguished tumor cell-intrinsic FAK expression from PYK2 enrichment in immune subsets. Together, these data position FAK as the dominant driver of IFN-γ-dependent resistance, with PYK2 playing a subsidiary role, and suggest that selective FAK targeting-potentially combined with limited PYK2 inhibition-may overcome immune checkpoint blockade resistance in melanoma.
引用
- Mizuno Y, Umemura M, Nagasako A, et al. Focal Adhesion Kinase-Dependent Reprogramming of IFN-γ Signaling through PYK2 Coinhibition Sensitizes Melanoma to Immune Checkpoint Blockade. J Invest Dermatol. 2025. PMID: 41101630. doi:10.1016/j.jid.2025.09.376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。